BAYER AG NA O.N.
Commented by Fabian Lorenz on July 14th, 2026 | 07:00 CEST
Bayer and Novo Nordisk Celebrate a Comeback! Is BioNxt Solutions Next?
With its GLP-1 therapy in tablet form, Novo Nordisk has returned to success on the stock market. Since April, the Danish pharmaceutical company's stock has risen by nearly 50% to around EUR 43. New research results are now being presented. Bayer has also recently celebrated a comeback on the stock market. Following the landmark glyphosate ruling by the US Supreme Court, hopes are growing that the company will be able to focus more strongly on its core business again in the future. To that end, the Leverkusen-based company has secured EUR 3 billion. BioNxt Solutions could be poised for a comeback. The biotech company's stock has nearly halved in value this year. Yet the news flow is positive and points to rising prices.
Read
Commented by Nico Popp on July 7th, 2026 | 07:15 CEST
This Market Is Growing 17.1% Annually: Bayer and KWS SAAT Rethink Their Strategies – MustGrow Biologics Gains Momentum
Created and published on behalf of MustGrow Biologics Corp.
It is not only drought that is putting pressure on farmers. Regulators are increasingly banning chemical active ingredients that have been used for decades in an effort to protect soils and consumers. Already, 168 countries have significantly restricted or completely banned the use of approximately 568 chemical pesticides. At the same time, the European Union aims to have at least 25% of its agricultural land farmed organically by 2030. As many highly effective products are being phased out, farmers around the world are facing growing challenges. The question of how to maintain crop yields under these changing conditions has become a key concern for industry. This trend is fueling the biopesticides market, which, according to current industry forecasts by Fortune Business Insights, is expected to grow at a compound annual growth rate (CAGR) of 17.1%, reaching USD 40.61 billion by 2034.
Read
Commented by Armin Schulz on July 4th, 2026 | 07:00 CEST
Fertilizer Crisis 2026: Why Bayer, MustGrow Biologics, and Yara International Belong on Investors' Watchlists
Created and published on behalf of MustGrow Biologics Corp.
The reopening of the Strait of Hormuz has come too late to prevent disruption. The weeks-long blockade has permanently destabilized the fragile fertilizer markets. During the crucial planting season, European agriculture is plagued by skyrocketing prices and empty warehouses. However, this shock is proving to be an enormous catalyst for a long-overdue change. As conventional chemical and fertilizer solutions face growing economic and regulatory challenges, biological alternatives are increasingly moving from the laboratory to commercial use. This turning point highlights three very different approaches within the global agricultural sector: the embattled industry heavyweight Bayer, the innovative agricultural biotech specialist MustGrow Biologics, and the fertilizer leader Yara International.
Read
Commented by Fabian Lorenz on July 1st, 2026 | 07:25 CEST
Bombshell, Buy Recommendation, and Upside Potential: RENK, Bayer, and Antimony Resources
Created and published on behalf of Antimony Resources Corp.
A major development has emerged at Antimony Resources. Until now, the investment case centred on the company's potential to develop a world-class antimony project in Canada. Now, gold has entered the picture as well. The analysis of approximately 190 sample intervals has revealed meaningful gold grades, providing investors with another compelling reason to consider the stock. Analysts see the potential for a multi-fold increase in its valuation. Analysts also see an attractive entry opportunity in RENK. In their view, the recent weakness in the share price following the sell-off in Rheinmetall has been overdone. The company could even report a new record in order intake. Meanwhile, the record-breaking lawsuits at Bayer could become more manageable in the future, following the recent US Supreme Court ruling. The stock responded with a strong rally, and analysts remain optimistic. Nevertheless, investors should bear in mind that not all legal cases have been resolved.
Read
Commented by André Will-Laudien on July 1st, 2026 | 06:50 CEST
Here We Go: A Breakthrough for Bayer, Buy Signals for MustGrow and Kraft Heinz
Created and Published on Behalf of MustGrow Biologics Corp.
According to United Nations projections, the world's population is expected to grow to around 9.7 billion people by 2050. The Food and Agriculture Organization (FAO) estimates that this growth can only be managed with significantly more productive and, at the same time, more sustainable farming methods. This is where MustGrow Biologics comes in with biological crop solutions based on natural mustard extracts. And the company's growth story is only just beginning. The sector is gaining short-term momentum now that Bayer has finally received a positive ruling from the US Supreme Court regarding glyphosate. This should allow the Leverkusen-based company's Crop Science division to really take off. At the same time, a powerful structural trend is reshaping the entire agricultural value chain. Natural resources and food must be produced more sustainably and with greater resilience to meet the nutritional needs of a rapidly growing global population. Companies such as Kraft Heinz are responding by leveraging decades of expertise in building resilient agricultural supply chains and climate-adaptive farming systems. These are exciting developments in a sector that is often overlooked in the shadow of high-tech and defence. But the technological trends have long since shifted!
Read
Commented by André Will-Laudien on June 29th, 2026 | 07:30 CEST
AI and M&A Frenzy in the Life Sciences Sector: Bayer, Vidac Pharma, Novo Nordisk, Evotec, and Eli Lilly
Yes, you read that correctly. Pharmaceutical companies are actively embracing artificial intelligence (AI) and, thanks to lower costs, better validation, and faster study setups, could emerge as winners of the new AI wave in the medium term. Many stocks in the life sciences sector had been overlooked by the market, but investors are now taking notice again. Eli Lilly is betting on AI and expanding its portfolio through targeted acquisitions, including the takeovers of sleep-wake specialist Centessa Pharmaceuticals and blood cancer specialist Ajax. At Evotec and Vidac Pharma, much of the focus is on cancer, while Novo Nordisk faces stiff competition from Eli Lilly's weight-loss drugs. Then came the welcome news regarding Bayer. The Supreme Court ruled that approximately 181,000 individual lawsuits alleging a lack of warning labels on packaging are no longer legally viable, as the US Environmental Protection Agency (EPA) has classified the herbicide glyphosate as safe. Lots of good news, and plenty of opportunities for active investors - we provide a few insights.
Read
Commented by Matthias Schomber on June 29th, 2026 | 06:45 CEST
Soaring Stock Prices, a Billion-Dollar Ruling, and the Green Transition: The Big Return Showdown Between Lufthansa, Bayer, and A.H.T. Syngas
Sometimes, a single court ruling is enough to fundamentally alter the outlook for a listed company. Bayer demonstrated this vividly this week. Meanwhile, Lufthansa is climbing to new annual highs, supported by falling oil prices and a surprisingly stable credit rating. Then there is A.H.T. Syngas, a small but ambitious provider of biomass power plants that has either just emerged from a consolidation phase, or may be approaching the end of one. Three very different companies, three distinct stages of development—yet all three are worth a closer look at this moment. If you want to understand where opportunities may lie and where caution is warranted, read on.
Read
Commented by Carsten Mainitz on June 25th, 2026 | 07:40 CEST
A Strong Duo in a Huge and Overlooked Growth Market: MustGrow Biologics and Bayer—When Will BayWa Recover?
Created and Published on Behalf of MustGrow Biologics Corp.
Global agriculture is undergoing a profound structural transformation. Climate change—marked by heat waves, droughts, and extreme weather events—is causing billions in crop losses annually in Europe alone. This is driving rising demand for more resilient farming systems and hardier crops. Regenerative agriculture and biological crop protection products are gaining strong momentum, forming the basis of emerging megatrends. According to expert estimates, the market for regenerative agriculture is expected to grow to around USD 50 billion by 2033. This is where the Canadian company MustGrow has positioned itself. Of particular importance is its licensing and development partnership with Bayer for biological crop protection solutions, which creates significant opportunities for this small-cap North American company.
Read
Commented by Armin Schulz on June 24th, 2026 | 08:30 CEST
Cancer remains the hottest bet in the pharmaceutical market: Bayer, Vidac Pharma, and Pfizer are competing for the next generation of therapies
The oncology market is the most dynamic segment of the pharmaceutical industry. While global heavyweights are positioning their multibillion-dollar pipelines, a small biotech company is banking on a scientific approach that directly targets the metabolism of tumour cells. For investors, the key question is whether the future of cancer treatment will be defined by broad-based therapies, targeted antibody-drug conjugates, or precise interventions at the cellular metabolic level. The differing approaches taken by Bayer, Vidac Pharma, and Pfizer promise to set the course not only medically but also financially for the coming decade.
Read
Commented by Nico Popp on June 19th, 2026 | 07:35 CEST
How MustGrow Biologics Benefits from Agrochemical Realignment with Patented Bioactive Technology – Pressure on Bayer and Corteva
Created and published on behalf of MustGrow Biologics Corp.
Extreme heat waves, increasingly degraded soils, and strict regulatory limits on synthetic chemical crop protection products—global agricultural markets are facing a critical period of adjustment. Once temperatures cross the critical threshold of 30 °C, most agricultural crops begin to suffer drastic yield losses, as sterile pollen and weakened cell walls cause irreparable damage to plant biology. According to the joint report by the Food and Agriculture Organization of the United Nations (FAO) and the World Meteorological Organization (WMO) titled "Extreme Heat and Agriculture," even individual heat waves can cause agricultural productivity to plummet by up to 50%. For most major crops, yield losses are already a threat at temperatures as low as 30 °C. The frequency, intensity, and duration of extreme heat events have increased significantly over the past 50 years. These ecological stressors are shifting growing conditions in both temperate and Mediterranean zones, forcing the entire agricultural value chain to rethink its approach.
Read